An interim analysis of this data shows no significant safety issues and a 91% seroconversion rate at Day 56.
The 41,000 sq ft facility will be utilized to manufacture clinical to commercial-grade peptide products for increased manufacturing capacity
This new €59 million, 70,000 square foot facility, officially opened today, brings 50 new jobs to the area
U.S. FDA has issued Form 483 with six observations after an inspection of the company’s formulation manufacturing facility based out of Baddi
Ex-Azithromycin has shown a growth of 8% and 14% in April 2022 and May 2022 respectively
The company is strategically expanding its product portfolio with a pipeline of new products that will form a strong foundation for future growth.
V116 designed to target serotypes that account for 85% of all invasive pneumococcal disease in individuals aged 65 and over in the United States as of 2019
The US FDA had conducted an inspection of Alkem Laboratories Limited's manufacturing facility located at St. Louis, USA.
This is the first Agilent lab to receive the My Green Lab Certification and plans are under way to certify additional labs.
LYNPARZA is approved in the U.S. for patients with HRR gene-mutated mCRPC (BRCA-mutated and other HRR gene mutations)
Bringing next-gen cannabinoid therapeutics to cancer patients
The company is now introducing the product into the India pharmaceutical market.
COR803 is a novel small molecule 3CLpro inhibitor discovered and developed by Cortexyme based on its expertise in cysteine protease inhibition.
It is only the second healthcare provider in the world to attain the Stage 6 DIAM certification.
The ground floor of the formulation development laboratory is focused on solid orals, the first floor on injections, and the second floor houses the analytical lab
Bioresource Technology's state of the art manufacturing facility in Weston, Florida
TRIPS waiver for five years agreed in the recently concluded WTO will help countries manufacture COVID vaccines to deal with the pandemic
With $120m jointly invested in the newly-formed initiative, and with other strategic investors expected to join, the venture will develop an alternative, plant-based ingredient using biotechnology
This investment will facilitate a Cipla entity's strategic participation in the Poe diagnostics and AMR space through the design, development, and manufacturing of microfluidics-based technologies
The company has a total sales of Rs. 25.8 crore during FY 21-22 and Rs. 26.4 crore during FY 20-21.
Subscribe To Our Newsletter & Stay Updated
